ABSTRACT

Background: The true frequency of adverse reactions (AR) attributed to antituberculosis drugs its unknown since they are seldom notified and therefore not reported. Material and methods: retrospective analysis of the files of the Tuberculosis Clinic at the Hospital General Tijuana to determine the frequency of AR in patients treated with a combination of first and second line antituberculosis drugs. Results: The most frequent AR to antituberculosis drugs were: renal dysfunction (75.9%), hepatitis (82.8%), hematologic abnormalities (79.3%), digestive AR (40%), hearing loss (26.7%), vestibular symptoms (15%) and tendinopathy (30%). Conclusions: AR to antituberculosis drugs are common and contribute to noncompliance. They must be routinely monitored and deal with, either with ancillary drugs, drug schedule modification and if needed with cessation of the offending drug.

KEYWORDS

Tuberculosis, drugs, adverse reactions, toxicity.

REFERENCES

1. Törün T, Güngör G, Özmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9(12):1373-1377.

2. Arbex MA, Varella M de C, Siqueira HR, Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: First-line drugs. J Bras Pneumol 2010;36(5):626-640.

3. Arbex MA, Varella M de C, Siqueira HR, Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: Second-line drugs. J Bras Pneumol 2010;36(5):641-656.

4. Farazi A, Sofian M, Jabbariasl M, Keshavarz S. Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients. Tuberc Res Treat 2014;2014:412893. doi: 10.1155/2014/412893.

5. Saukkonen JJ, Cohn DL, Jasmer RM, et al.; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174(8):935-952.

6. Shean K, Streicher E, Pieterson E, et al. Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS One 2013;8(5):e63057. doi: 10.1371/journal.pone.0063057.

7. Laniado-Laborín R. Adverse effects and toxicity of antituberculosis drugs. In: Drug resistant tuberculosis. Practical guide for clinical management. ISBN 978-1-68108-067-3. Bentham e-books: 2015. p. 74-84.

8. Shang P, Xia Y, Liu F, et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One 2011;6(7):e21836. doi: 10.1371/journal.pone.0021836.

9. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999;43(5):1003-1012.

10. Xie J, Talaska AE, Schacht J. New developments in aminoglycoside therapy and ototoxicity. Hear Res 2011;281(1-2):28-37. doi: 10.1016/j.heares.2011.05.008.

11. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003;36(11):1404-1410.

12. Curry International Tuberculosis Center and California Department of Public Health. Adverse reactions. In: California Public Health Department, editors. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. 3rd ed. USA; 2016: p. 146-171.

13. Laniado-Laborín R. Efectos adversos y toxicidad de los fármacos antituberculosis. En: El ABC de la tuberculosis resistente a los fármacos: Manual práctico de diagnóstico y tratamiento. ISBN-10: 3848459884. Editorial Académica Española; 2012: p.78-92.